Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pharmacokinetics of ASP2215”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Early research (Phase 1)Study completedNCT02571816
What this trial is testing

Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Who this might be right for
Hepatic ImpairmentHealthy
Astellas Pharma Global Development, Inc. 24
Early research (Phase 1)Study completedNCT04699877
What this trial is testing

Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Who this might be right for
Renal ImpairedGilteritinibNormal Renal Function+1 more
Astellas Pharma Global Development, Inc. 17
Early research (Phase 1)Study completedNCT02456883
What this trial is testing

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsPharmacokinetics of 14C-labeled Gilteritinib
Astellas Pharma Global Development, Inc. 6
Testing effectiveness (Phase 2)Ended earlyNCT05028751
What this trial is testing

Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Kronos Bio 24
Early research (Phase 1)Study completedNCT02181660
What this trial is testing

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Astellas Pharma Inc 24
Early research (Phase 1)Study completedNCT03625505
What this trial is testing

Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
AbbVie 61
Testing effectiveness (Phase 2)Study completedNCT02014558
What this trial is testing

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 265